QualityStocksNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $6 Million Public Offering
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines, announced the pricing of an underwritten public offering for gross proceeds of $6 million before expenses. The offering includes about 1.47 million common stock units priced at $2.00 each and about 1.53 million pre-funded warrant units priced at $1.999 each, both paired with Series I warrants exercisable at $2.00 per share for five years. Ladenburg Thalmann is serving as sole book-running manager with Laidlaw & Company (U.K.) Ltd. as co-manager. To view the full press release, visit https://ibn.fm/qMaHi About Calidi Biotherapeutics Calidi Biotherapeutics…